Cannabidiol in epilepsy: The indications and beyond

Research output: Contribution to journalReview articlepeer-review


Epilepsy, although common, remains difficult to treat with as much as 30% of patients having treatment-resistant conditions. Lennox-Gastaut syndrome and Dravet syndrome are childhood-onset epilepsies and among the most difficult to treat. Cannabidiol has been approved by the Food and Drug Administration to treat these conditions in individuals over 2 years of age; however, there is a great deal of interest in off-label use. This article examines 3 cases: 1 of a patient with Lennox-Gastaut syndrome, 1 of off-label use of cannabidiol to treat epilepsy, and 1 of nonprescription forms of cannabidiol to treat epilepsy.
Original languageAmerican English
Pages (from-to)317-325
JournalMental Health Clinician
Issue number6
StatePublished - Nov 5 2020


  • epilepsy
  • treatment-resistant epilepsy
  • cannabidiol
  • Cannabinoids
  • Lennox-Gastaut syndrome
  • Dravet syndrome


Dive into the research topics of 'Cannabidiol in epilepsy: The indications and beyond'. Together they form a unique fingerprint.

Cite this